AKL4 Market Opportunity

Osteoarthritis (OA) incidence increases with obesity and longevity (~40% >65yrs have knee/hip OA) representing a serious burden on global healthcare systems. OA will be the 4th leading cause of UK disability by 2020.

Osteoarthritis represents an increasing economic burden with direct and indirect costs in the USA, Canada, UK, France and Australia accounting for between 1-2.5% of gross national product.

For more information on OA, please visit Arthritis Research UK.

Osteoarthritis (OA) is a flaring, degenerative & chronic arthropathy that is one of the leading causes of pain and disability worldwide. It affects ~10% of the global population >60yrs and ~15% of the UK population >25yrs (~50% diagnosed + receiving treatment).

Many patients rotate through several agents due to insufficient efficacy, adverse side effects and/or use unproven complementary therapies.

Following the withdrawal of a number of medicines for treating OA, a significant unmet medical need continues to exist for inflammation and pain relief associated with OA. After many years of research to identify new anti-inflammatory drugs, corticosteroids and NSAIDs (non-steroidal anti-inflammatory drugs) are still the main agents used to control inflammation.

Single drug therapeutics are rarely able to fully address the complex nature of most human diseases. Cellular pathways operate more like webs than superhighways. There are multiple redundancies, or alternate routes, that may be activated in response to the inhibition of a pathway.

Advances in genomics and cell biology have increased the opportunity for rational design of targeted drugs to inhibit the function of specific molecules. Although targeted therapies may offer enhanced efficacy and improved selectivity (and therefore less toxicity), most often their effects are not durable when they are used alone.